SWISSTO12
19.5.2023 14:01:34 CEST | Business Wire | Press release
Inmarsat, a world leader in global, mobile satellite communications, has announced that SWISSto12, one of Europe’s fastest growing aerospace providers, will develop its new eighth-generation of spacecraft. The three I-8 satellites will provide additional network resilience, securing the future of Inmarsat’s global L-band safety services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005018/en/
An illustration of SWISSto12's HummingSat in geostationary orbit. Image credit: SWISSto12
SWISSto12, headquartered in Switzerland, will use its HummingSat satellite platform - in conjunction with unique 3D-printing technologies and specialised Radio-Frequency (RF) and payload products - to develop and manufacture the geostationary satellites, which will launch by 2026.
Just 1.5 cubic metres in volume, the I-8’s will use SWISSto12’s innovative new class of spacecraft which has a form factor up to five times smaller than conventional geostationary satellites yet can still deliver critical safety services with certainty.
The three l-8 satellites will continue to provide the extra layer of resilience to complement the existing constellation and Inmarsat’s two I-6 generation satellites, which were launched in December 2021 and February 2023. In March 2023, Inmarsat announced the first, I-6 F1, had successfully completed testing with ground stations in Western Australia and has now started to provide Ka-band services for the fast-growing Asia Pacific region. The company will begin introducing its L-band capacity and transitioning services to the new satellite throughout 2023.
The second, I-6 F2, which launched in February 2023, is expected to enter operational service over Europe, Africa, and much of the Americas in early 2024.
Each I-8 will also extend Inmarsat’s history of launching and operating radionavigation transponders for Governments and international space agencies. These transponders can enable Satellite-Based Augmentation System (SBAS) services around the world, for example for air traffic controllers or coastguards. SBAS systems uses satellite connectivity, land-based infrastructure, and software to enhance standard GPS/Galileo accuracy of 5 to 10 metres to as little as just 10cm.
Such precise tracking could enable pinpoint safety navigation on aircraft, help emergency services reach vessels in distress more quickly, or allow a raft of industrial innovations, like device tracking in agriculture or advanced, automated transport management systems.
The I-8 satellites will continue to secure Inmarsat’s global safety services into the 2040’s. The company was founded in 1979 under the auspices of the United Nations specifically to provide highly reliable safety communications. Today some 1.6 million seafarers and over 200 airlines rely on Inmarsat’s global L-band network to deliver 99.9% availability every day.
The Inmarsat-8 programme forms part of Inmarsat’s fully-funded technology roadmap, which will include five new satellite payloads added by 2025 to further Inmarsat’s high-speed broadband Global Xpress (GX) network with the launch of the software defined satellites GX 7,8, and 9, aimed for 2025, and the polar coverage satellites GX10a and b, which are aimed for the first half of 2024.
Peter Hadinger, Chief Technology Officer, Inmarsat, said “Every single day people around the world depend on Inmarsat services. Our customers have demanding, and often safety critical, missions that rely on our satellite technology for links that can make the difference. The I-8’s will not only underpin our existing capabilities for the future; but enable ever more advanced safety innovations like SBAS that can ultimately help save more lives. We have chosen SWISSto12 because they have the ground-breaking technology that can make it a reality.”
Emile de Rijk, CEO, SWISSto12, said “We are delighted that Inmarsat has selected SWISSto12 as its partner for its landmark l-8 program. It demonstrates that, with HummingSat, we have created a highly-advanced new class of small geostationary spacecraft that delivers world-leading connectivity capabilities at a fraction of the cost. Our proprietary 3D-printing of Radio Frequency payload technology allows us to push the limits of existing capability and service new and existing business cases for geostationary satellite communications. This is an important step in our journey to better connect and protect every corner of the world.”
ENDS
ABOUT INMARSAT
Inmarsat delivers world leading, innovative, advanced and exceptionally reliable global, mobile communications across the world – in the air, at sea and on land - that are enabling a new generation of commercial, government and mission-critical services. Inmarsat is powering the digitalisation of the maritime industry, making operations more efficient and safer than ever before. It is driving a new era of inflight passenger services for aviation, while ensuring that aircraft can fly with maximum efficiency and safety. Furthermore, Inmarsat is enabling the rapid expansion of the Internet of Things (IoT) and enabling the next wave of world-changing technologies that will underpin the connected society and help build a sustainable future. And now Inmarsat is developing the first-of-its-kind, multi-dimensional communications network of the future, ORCHESTRA.
In November 2021, Inmarsat and Viasat announced the planned combination of the two companies, to create a new leader in global communications.
For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.
ABOUT SWISSto12
SWISSto12 is a leading manufacturer of advanced satellite payloads and systems, including the HummingSat: a small yet powerful geostationary telecommunications satellite developed in collaboration with the European Space Agency (ESA) through its public-private-partnership program. The first commercial customer of HummingSat was announced in November 2022. The company’s satellites and payloads benefit from unique and patented 3D-printing technologies and associated Radio Frequency (RF) product designs that deliver lightweight, compact, highly performing, and competitive RF functionality. Besides its space portfolio, the company is also active in telecommunications, surveillance and radar applications for the aeronautic industry. SWISSto12 has developed commercially with success in Europe, the USA and Israel and is amongst the fastest growing aerospace companies in Europe. SWISSto12 spun off in 2011 from the Swiss Federal Institute of Technology in Lausanne (EPFL), is privately owned and backed by prominent Swiss and European Investors.
For further information, visit https://swissto12.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005018/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
